You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

    SBC: PAPGENE, INC.            Topic: NCI

    This proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyz ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A novel biomaterial based therapy utilizing auto antigen and adjuvant for the amelioration of Type Diabetes

    SBC: ONEVAX, LLC            Topic: NIAID

    Immune mediated diseases such as type diabetes T D multiple sclerosis rheumatoid arthritis and systemic lupus erythematosis are reaching epidemic proportions in the US T D affects an estimated million Americans with more than new patients diagnosed annually resulting in roughly $ B in health care costs in the US each year T D is an autoimmune disease characterized by effector ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. A Yeast based Immunotherapy against Clostridium difficile Infection

    SBC: FZATA INC            Topic: NIAID

    Abstract Antibacterial resistance is a global public health crisis Antibiotic resistant Clostridium difficile is responsible for more than deaths in US each year and the infection represents an urgent threat to public health worldwide Of most concern is that the incidence of C difficile infection CDI and disease severity is rapidly increasing in recent years due to the emergence of hy ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluation of Natural Products and Derivatives as Antimalarial Agents

    SBC: Cascade Therapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY The proposed research focuses on the development of novel therapeutic agents for the treatment of malaria caused by P falciparum Preliminary studies have discovered some novel natural products and derivative molecules with potent in vitro activity against both sensitive and multidrug resistant malaria strains including the newly emerging artemisinin resistant parasite line New ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Strategies to Improve Production of a Full Length Native HIV Env Spike

    SBC: CODEX BIOSOLUTIONS            Topic: R

    Project Summary Production of HIV envelope protein Env trimeric gp cleaved to gp gp for clinical studies is a critical objective for vaccine development Its conformational plasticity which allows it to adopt multiple conformational states important for function often makes its expression and purification very difficult Our recent work shows a route for overcoming this probl ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Serotype independent therapeutic vaccine for Streptococcus pneumoniae

    SBC: Integrated Biotherapeutics, Inc.            Topic: R

    In the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among vaccinated populationsor because many simply don t get vaccinatedThusinno ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development and Validation of a Collaborative Web-Based Quantitative Imaging and Dosimetry System for Radiopharmaceutical Therapy

    SBC: RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC            Topic: NCI

    Radiopharmaceutical therapyRPTis an emerging cancer treatment that delivers radiation directly to cancer cellsThe recent FDA approval ofRa Xofigotmfor resistant metastatic prostate cancer and its commercial success provides an example of the therapeutic and commercial potential of this modalityIn additiondrug companies have large libraries of targets and targeting moleculesProgress in chelators an ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. An interactive App to Promote Safe and Effective use of Opioids in Young Children Postoperatively

    SBC: ARCHIE MD INC.            Topic: NIDA

    In recent years increased attention to pain in children and adolescents has led to a recent fold increase in opioid prescriptions Unsurprisingly the annual rates of analgesic related adverse drug events AR ADEs have soared to include andgt hospital admissions and hundreds of accidental overdose deaths in children and adolescents and has remained a significant problem At the heart of ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    Significance Despite decreases in the overall number of new breast cancer BC cases reported in the US annually there are still about BC deaths annually from metastatic breast cancer MBC Thus the ability to monitor MBC is important to determine disease status and therapy response While the gold standard imaging is expensive time consuming and slow to detect disease response o ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government